{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jeon SM"],"funding":["Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute","the Ministry of Health &amp; Welfare, Republic of Korea"],"pagination":["1966-1984"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9673965"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["Ohmyungsamycin A (OMS) is a newly identified cyclic peptide that exerts antimicrobial effects against <i>Mycobacterium tuberculosis</i>. However, its role in nontuberculous mycobacteria (NTMs) infections has not been clarified. <i>Mycobacteroides abscessus</i> (Mabc) is a rapidly growing NTM that has emerged as a human pathogen in both immunocompetent and immunosuppressed individuals. In this study, we demonstrated that OMS had significant antimicrobial effects against Mabc infection in both immunocompetent and immunodeficient mice, and in macrophages. OMS treatment amplified Mabc-induced expression of M1-related proinflammatory cytokines and inducible nitric oxide synthase, and significantly downregulated arginase-1 expression in murine macrophages. In addition, OMS augmented Mabc-mediate"],"journal":["Virulence"],"pubmed_title":["Ohmyungsamycin promotes M1-like inflammatory responses to enhance host defence against <i>Mycobacteroides abscessus</i> infections."],"pmcid":["PMC9673965"],"funding_grant_id":["HI22C1361"],"pubmed_authors":["Kim JM","Jo EK","Jeon SM","Kim YJ","Cui J","Kim JK","Silwal P","Jang J","Thi Bich Hanh B","Nguyen TQ","Oh DC"],"additional_accession":[]},"is_claimable":false,"name":"Ohmyungsamycin promotes M1-like inflammatory responses to enhance host defence against <i>Mycobacteroides abscessus</i> infections.","description":"Ohmyungsamycin A (OMS) is a newly identified cyclic peptide that exerts antimicrobial effects against <i>Mycobacterium tuberculosis</i>. However, its role in nontuberculous mycobacteria (NTMs) infections has not been clarified. <i>Mycobacteroides abscessus</i> (Mabc) is a rapidly growing NTM that has emerged as a human pathogen in both immunocompetent and immunosuppressed individuals. In this study, we demonstrated that OMS had significant antimicrobial effects against Mabc infection in both immunocompetent and immunodeficient mice, and in macrophages. OMS treatment amplified Mabc-induced expression of M1-related proinflammatory cytokines and inducible nitric oxide synthase, and significantly downregulated arginase-1 expression in murine macrophages. In addition, OMS augmented Mabc-mediate","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-25T21:05:11.405Z","creation":"2025-04-06T08:35:18.066Z"},"accession":"S-EPMC9673965","cross_references":{"pubmed":["36271707"],"doi":["10.1080/21505594.2022.2138009"]}}